[SCHEDULE 13G/A] Dianthus Therapeutics, Inc. SEC Filing
Dianthus Therapeutics, Inc. Schedule 13G/A reports that Point72-related entities and Steven A. Cohen collectively have shared voting and dispositive power over 1,445,825 shares of Dianthus common stock, representing 4.5% of the class as of the close of business on June 30, 2025. The filing states the shares are held by an investment fund managed by Point72 Asset Management; Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management and Mr. Cohen controls both entities. Each reporting person reports 0 sole voting and 0 sole dispositive power, with all reported power listed as shared. The statement clarifies the filing should not be construed as admission of beneficial ownership for purposes of Section 13.
Dianthus Therapeutics, Inc. - Nel modulo Schedule 13G/A si segnala che entit脿 collegate a Point72 e Steven A. Cohen detengono congiuntamente il potere di voto e dispositivi su 1.445.825 azioni ordinarie di Dianthus, pari a il 4,5% della categoria alla chiusura delle contrattazioni del 30 giugno 2025. La dichiarazione indica che le azioni sono in capo a un fondo d鈥檌nvestimento gestito da Point72 Asset Management; Point72 Capital Advisors, Inc. 猫 la societ脿 generale di Point72 Asset Management e il sig. Cohen esercita controllo su entrambe le entit脿. Ciascun dichiarante riporta 0 voti esclusivi e 0 poteri dispositivi esclusivi, con tutti i poteri indicati come condivisi. Si precisa che la comunicazione non costituisce ammissione di titolarit脿 effettiva ai sensi della Sezione 13.
Dianthus Therapeutics, Inc. - El Schedule 13G/A informa que entidades relacionadas con Point72 y Steven A. Cohen comparten colectivamente el poder de voto y dispositivo sobre 1.445.825 acciones comunes de Dianthus, representando el 4,5% de la clase al cierre de mercado del 30 de junio de 2025. La presentaci贸n indica que las acciones est谩n en un fondo gestionado por Point72 Asset Management; Point72 Capital Advisors, Inc. es la sociedad gestora general de Point72 Asset Management y el Sr. Cohen controla ambas entidades. Cada declarante informa 0 voto exclusivo y 0 poder dispositivo exclusivo, quedando todo el poder reportado como compartido. Se aclara que la presentaci贸n no debe interpretarse como una admisi贸n de propiedad beneficiaria a efectos de la Secci贸n 13.
Dianthus Therapeutics, Inc. - Schedule 13G/A 氤搓碃靹滌棎 霐半ゴ氅� Point72 甏�霠� 氩曥澑霌り臣 鞀ろ嫲敫� A. 旖旐棬鞚� 頃粯 1,445,825欤�鞚� Dianthus 氤错喌欤检棎 雽�頃� 鞚橁舶甓� 氚� 觳橂秳甓岇潉 瓿惦彊鞙茧 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 2025雲� 6鞗� 30鞚� 鞛� 毵堦皭 旮办 齑� 氚滍枆欤检嫕鞚� 4.5%鞐� 頃措嫻頃╇媹雼�. 鞝滌稖靹滌棎電� 頃措嫻 欤检嫕鞚� Point72 Asset Management臧� 鞖挫毄頃橂姅 韴瀽韼�霌滌棎 靻嶍暅雼り碃 旮办灛霅橃柎 鞛堨溂氅�, Point72 Capital Advisors, Inc.電� Point72 Asset Management鞚� 鞝滊剤霟� 韺岉姼雱堨澊瓿� 旖旐棬 鞌皜 霊� 氩曥澑鞚� 韱奠牅頃滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 臧� 氤搓碃鞛愲姅 雼弲 鞚橁舶甓� 0 氚� 雼弲 觳橂秳甓� 0鞚� 氤搓碃頄堨溂氅�, 氤搓碃霅� 氇摖 甓岉暅鞚� 瓿惦彊 甓岉暅鞙茧 響滉赴霅橃柎 鞛堨姷雼堧嫟. 鞚� 鞝滌稖鞚� 靹轨厴 13鞚� 氇╈爜靸� 鞁れ鞝� 靻岇湢甓岇潣 鞚胳爼鞙茧 頃挫劃霅橃柎靹滊姅 鞎� 霅滊嫟瓿� 氇呾嫓頃╇媹雼�.
Dianthus Therapeutics, Inc. - Le Schedule 13G/A indique que des entit茅s li茅es 脿 Point72 et Steven A. Cohen d茅tiennent conjointement le pouvoir de vote et de disposition sur 1 445 825 actions ordinaires de Dianthus, soit 4,5 % de la cat茅gorie 脿 la cl么ture des march茅s le 30 juin 2025. Le d茅p么t pr茅cise que les actions sont d茅tenues par un fonds d鈥檌nvestissement g茅r茅 par Point72 Asset Management ; Point72 Capital Advisors, Inc. est le partenaire g茅n茅ral de Point72 Asset Management et M. Cohen contr么le les deux entit茅s. Chaque d茅clarant signale 0 pouvoir de vote exclusif et 0 pouvoir de disposition exclusif, tous les pouvoirs 茅tant d茅clar茅s comme partag茅s. Il est pr茅cis茅 que cette d茅claration ne doit pas 锚tre interpr茅t茅e comme une reconnaissance d鈥檜ne propri茅t茅 b茅n茅ficiaire au sens de la Section 13.
Dianthus Therapeutics, Inc. - In der Schedule 13G/A wird berichtet, dass Point72-nahe Einheiten und Steven A. Cohen zusammen die Stimm- und Verf眉gungsgewalt 眉ber 1.445.825 Aktien der Dianthus-Stammaktien innehaben, was zum B枚rsenschluss am 30. Juni 2025 4,5 % der Klasse entspricht. Die Einreichung gibt an, dass die Aktien von einem von Point72 Asset Management verwalteten Investmentfonds gehalten werden; Point72 Capital Advisors, Inc. ist der Generalpartner von Point72 Asset Management und Herr Cohen 眉bt Kontrolle 眉ber beide Einheiten aus. Jeder Meldende gibt 0 alleinige Stimmrechte und 0 alleinige Verf眉gungsrechte an; alle gemeldeten Rechte sind als gemeinsam ausgewiesen. Es wird klargestellt, dass die Meldung nicht als Anerkennung einer wirtschaftlichen Eigent眉merschaft im Sinne von Abschnitt 13 zu verstehen ist.
- Transparent disclosure of holdings: 1,445,825 shares reported with specific shared voting and dispositive power
- Clear chain of control identified: Point72 Asset Management manages the fund, Point72 Capital Advisors is general partner, and Steven A. Cohen controls the entities
- Position below 5% threshold (4.5%), consistent with passive reporting under Schedule 13G/A
- None.
Insights
TL;DR: Point72 reports a 4.5% shared stake in Dianthus, a non-controlling position below the 5% threshold.
Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen disclose shared voting and dispositive power over 1,445,825 shares as of June 30, 2025. The filing shows no sole voting or dispositive power and explicitly notes the position is not intended to influence control of the issuer. Because the stake is under 5%, this is a routine Section 13G disclosure reflecting passive or qualifying investor status rather than an active acquisition or control intent. Investors should view this as a transparency filing rather than a material change to corporate control.
TL;DR: Disclosure is complete and consistent with passive ownership reporting; ownership structure shows common control through Point72 entities.
The document identifies the reporting chain: Point72 Asset Management manages the fund owning the shares, Point72 Capital Advisors is the general partner, and Steven A. Cohen controls those entities. The certification clarifies the securities were not acquired to change control. All signatures are executed by an authorized person. From a governance perspective, the filing documents influence via shared powers but does not indicate an active control campaign.
Dianthus Therapeutics, Inc. - Nel modulo Schedule 13G/A si segnala che entit脿 collegate a Point72 e Steven A. Cohen detengono congiuntamente il potere di voto e dispositivi su 1.445.825 azioni ordinarie di Dianthus, pari a il 4,5% della categoria alla chiusura delle contrattazioni del 30 giugno 2025. La dichiarazione indica che le azioni sono in capo a un fondo d鈥檌nvestimento gestito da Point72 Asset Management; Point72 Capital Advisors, Inc. 猫 la societ脿 generale di Point72 Asset Management e il sig. Cohen esercita controllo su entrambe le entit脿. Ciascun dichiarante riporta 0 voti esclusivi e 0 poteri dispositivi esclusivi, con tutti i poteri indicati come condivisi. Si precisa che la comunicazione non costituisce ammissione di titolarit脿 effettiva ai sensi della Sezione 13.
Dianthus Therapeutics, Inc. - El Schedule 13G/A informa que entidades relacionadas con Point72 y Steven A. Cohen comparten colectivamente el poder de voto y dispositivo sobre 1.445.825 acciones comunes de Dianthus, representando el 4,5% de la clase al cierre de mercado del 30 de junio de 2025. La presentaci贸n indica que las acciones est谩n en un fondo gestionado por Point72 Asset Management; Point72 Capital Advisors, Inc. es la sociedad gestora general de Point72 Asset Management y el Sr. Cohen controla ambas entidades. Cada declarante informa 0 voto exclusivo y 0 poder dispositivo exclusivo, quedando todo el poder reportado como compartido. Se aclara que la presentaci贸n no debe interpretarse como una admisi贸n de propiedad beneficiaria a efectos de la Secci贸n 13.
Dianthus Therapeutics, Inc. - Schedule 13G/A 氤搓碃靹滌棎 霐半ゴ氅� Point72 甏�霠� 氩曥澑霌り臣 鞀ろ嫲敫� A. 旖旐棬鞚� 頃粯 1,445,825欤�鞚� Dianthus 氤错喌欤检棎 雽�頃� 鞚橁舶甓� 氚� 觳橂秳甓岇潉 瓿惦彊鞙茧 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 2025雲� 6鞗� 30鞚� 鞛� 毵堦皭 旮办 齑� 氚滍枆欤检嫕鞚� 4.5%鞐� 頃措嫻頃╇媹雼�. 鞝滌稖靹滌棎電� 頃措嫻 欤检嫕鞚� Point72 Asset Management臧� 鞖挫毄頃橂姅 韴瀽韼�霌滌棎 靻嶍暅雼り碃 旮办灛霅橃柎 鞛堨溂氅�, Point72 Capital Advisors, Inc.電� Point72 Asset Management鞚� 鞝滊剤霟� 韺岉姼雱堨澊瓿� 旖旐棬 鞌皜 霊� 氩曥澑鞚� 韱奠牅頃滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 臧� 氤搓碃鞛愲姅 雼弲 鞚橁舶甓� 0 氚� 雼弲 觳橂秳甓� 0鞚� 氤搓碃頄堨溂氅�, 氤搓碃霅� 氇摖 甓岉暅鞚� 瓿惦彊 甓岉暅鞙茧 響滉赴霅橃柎 鞛堨姷雼堧嫟. 鞚� 鞝滌稖鞚� 靹轨厴 13鞚� 氇╈爜靸� 鞁れ鞝� 靻岇湢甓岇潣 鞚胳爼鞙茧 頃挫劃霅橃柎靹滊姅 鞎� 霅滊嫟瓿� 氇呾嫓頃╇媹雼�.
Dianthus Therapeutics, Inc. - Le Schedule 13G/A indique que des entit茅s li茅es 脿 Point72 et Steven A. Cohen d茅tiennent conjointement le pouvoir de vote et de disposition sur 1 445 825 actions ordinaires de Dianthus, soit 4,5 % de la cat茅gorie 脿 la cl么ture des march茅s le 30 juin 2025. Le d茅p么t pr茅cise que les actions sont d茅tenues par un fonds d鈥檌nvestissement g茅r茅 par Point72 Asset Management ; Point72 Capital Advisors, Inc. est le partenaire g茅n茅ral de Point72 Asset Management et M. Cohen contr么le les deux entit茅s. Chaque d茅clarant signale 0 pouvoir de vote exclusif et 0 pouvoir de disposition exclusif, tous les pouvoirs 茅tant d茅clar茅s comme partag茅s. Il est pr茅cis茅 que cette d茅claration ne doit pas 锚tre interpr茅t茅e comme une reconnaissance d鈥檜ne propri茅t茅 b茅n茅ficiaire au sens de la Section 13.
Dianthus Therapeutics, Inc. - In der Schedule 13G/A wird berichtet, dass Point72-nahe Einheiten und Steven A. Cohen zusammen die Stimm- und Verf眉gungsgewalt 眉ber 1.445.825 Aktien der Dianthus-Stammaktien innehaben, was zum B枚rsenschluss am 30. Juni 2025 4,5 % der Klasse entspricht. Die Einreichung gibt an, dass die Aktien von einem von Point72 Asset Management verwalteten Investmentfonds gehalten werden; Point72 Capital Advisors, Inc. ist der Generalpartner von Point72 Asset Management und Herr Cohen 眉bt Kontrolle 眉ber beide Einheiten aus. Jeder Meldende gibt 0 alleinige Stimmrechte und 0 alleinige Verf眉gungsrechte an; alle gemeldeten Rechte sind als gemeinsam ausgewiesen. Es wird klargestellt, dass die Meldung nicht als Anerkennung einer wirtschaftlichen Eigent眉merschaft im Sinne von Abschnitt 13 zu verstehen ist.
FAQ
How many Dianthus (DNTH) shares do Point72 and Steven A. Cohen report?
Does the Schedule 13G/A indicate Point72 seeks control of Dianthus (DNTH)?
What voting and dispositive powers are reported by the filers?
Which Point72 entities are named in the filing for DNTH?
As of what date are the reported holdings for DNTH effective?
